Q3 Earnings Forecast for Genmab A/S Issued By HC Wainwright

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Stock analysts at HC Wainwright decreased their Q3 2026 EPS estimates for shares of Genmab A/S in a research report issued to clients and investors on Wednesday, October 7th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $0.48 per share for the quarter, down from their previous forecast of $0.49. HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.21 per share. HC Wainwright also issued estimates for Genmab A/S’s Q4 2026 earnings at $0.42 EPS and FY2026 earnings at $1.45 EPS.

A number of other research firms also recently issued reports on GMAB. Weiss Ratings raised Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, September 1st. New Street Research set a $43.00 price objective on Genmab A/S in a report on Wednesday, July 22nd. Guggenheim upped their price objective on shares of Genmab A/S from $45.00 to $54.00 and gave the stock a “buy” rating in a research note on Monday. TD Cowen upgraded shares of Genmab A/S from a “hold” rating to a “buy” rating and increased their target price for the stock from $32.00 to $43.00 in a report on Wednesday, July 22nd. Finally, Truist Financial raised their target price on shares of Genmab A/S from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $42.50.

Genmab A/S Stock Down 1.6%

Shares of NASDAQ:GMAB opened at $36.05 on Friday. The business’s 50 day moving average is $33.45 and its 200 day moving average is $29.30. The stock has a market cap of $22.50 billion, a P/E ratio of 28.39, a price-to-earnings-growth ratio of 1.69 and a beta of 0.81. Genmab A/S has a 52-week low of $23.62 and a 52-week high of $40.17. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Thursday, August 6th. The company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.17. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.12 billion. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%.

Institutional Investors Weigh In On Genmab A/S

A number of hedge funds have recently made changes to their positions in GMAB. Arrowstreet Capital Limited Partnership raised its holdings in Genmab A/S by 36.6% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock worth $153,324,000 after purchasing an additional 1,334,919 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Genmab A/S by 26.4% in the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock valued at $118,442,000 after buying an additional 921,700 shares in the last quarter. First Trust Advisors LP grew its position in shares of Genmab A/S by 84.3% in the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock worth $66,038,000 after buying an additional 1,126,069 shares during the last quarter. Quantinno Capital Management LP grew its position in shares of Genmab A/S by 14.4% in the 1st quarter. Quantinno Capital Management LP now owns 282,498 shares of the company’s stock worth $7,579,000 after buying an additional 35,588 shares during the last quarter. Finally, Royal Bank of Canada raised its stake in shares of Genmab A/S by 1.8% during the 1st quarter. Royal Bank of Canada now owns 150,135 shares of the company’s stock worth $4,029,000 after acquiring an additional 2,637 shares in the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to create therapies designed to engage the immune system, target disease-related proteins and improve treatment outcomes.

Genmab’s portfolio includes products developed through partnerships as well as internally discovered candidates.